<- Go Home
CinCor Pharma, Inc.
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc.
Market Cap
$1.3B
Volume
232.3K
Cash and Equivalents
$292.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$43.15
52 Week Low
$10.53
Dividend
N/A
Price / Book Value
2.45
Price / Earnings
-9.39
Price / Tangible Book Value
2.45
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$82.5M
Return on Equity
26.91%
Return on Assets
-15.25
Cash and Short Term Investments
$522.5M
Debt
N/A
Equity
$518.9M
Revenue
N/A
Unlevered FCF
-$49.5M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium